International Flavors & Fragrances Reports Q2 2026 Results; Sells Food Ingredients to CVC

What Happened
International Flavors & Fragrances Inc. (IFF) filed an 8‑K on August 4, 2026 furnishing a press release reporting the company's financial results for the quarter ended June 30, 2026 and announcing a webcast to discuss second‑quarter results on August 5, 2026 at 9:00 a.m. ET. Separately, IFF announced that on May 29, 2026 it entered into a Purchase Agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners. IFF will retain an approximately 10% minority equity interest in the sold business. The sale is expected to close by the end of Q2 2027, subject to customary closing conditions and regulatory approvals.

Key Details

• Press release dated August 4, 2026; live webcast on August 5, 2026 at 9:00 a.m. ET; recorded replay available about one hour after and for one year on ir.iff.com.
• Purchase Agreement signed May 29, 2026 to sell substantially all assets and certain liabilities of the Food Ingredients business to CVC‑advised funds.
• IFF will retain ~10% equity in the business to permit ongoing collaboration and to share in future value creation.
• IFF concluded the Food Ingredients disposal group meets held‑for‑sale criteria and the sale is a strategic shift with a major effect; accordingly, Food Ingredients results are presented as discontinued operations for all periods presented.

Why It Matters
The divestiture of the Food Ingredients business is a material strategic change that will alter IFF’s revenue and profit mix going forward; presenting that business as discontinued operations will affect comparability of quarterly results and reported earnings. Retaining a ~10% stake means IFF may still benefit from future growth of the sold business while shifting capital and management focus. Investors should review the August 4 press release and the August 5 webcast for the detailed quarterly earnings figures and management commentary on how the transaction and discontinued‑operations treatment impact near‑term financials.